GlycoMimetics, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
13.40
+0.13 (0.98%)
Jun 18, 2025, 11:50 AM - Market open
Company Description
As of June 16, 2025, GlycoMimetics, Inc. was acquired by Crescent Biopharma, Inc., in a reverse merger transaction.
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States.
The company was founded in 2003 and is based in Monrovia, Maryland.
GlycoMimetics, Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
Contact Details
Address: P.O. Box 65 Monrovia, Maryland 21770 United States | |
| Phone | 240 243 1201 |
| Website | glycomimetics.com |
Stock Details
| Ticker Symbol | CBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001124105 |
| CUSIP Number | 14888D208 |
| ISIN Number | US4037831033 |
| Employer ID | 56-2020050 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nassim Usman Ph.D. | President, Chief Executive Officer and Director |
| Seline E. Miller CPA | Senior Vice President of Finance, Interim Chief Financial and Principal Accounting Officer |
| Dr. Grant Blouse M.Sc., Ph.D. | Chief Scientific Officer |
| Ana Kapor | Senior Director of Investor Relations and Corporate Communications |
| Dr. Tom Knudsen D.V.M., Ph.D. | Senior Vice President of Corporate Development |